DAFNA Capital Management »

Maze Therapeatics shares owned by DAFNA Capital Management

Quarter-by-quarter ownership of Maze Therapeatics (MAZE) shares owned by DAFNA Capital Management from 13F filings

Historical chart of DAFNA Capital Management investment in Maze Therapeatics

Tip: Access up to 7 years of quarterly data

All positions including Maze Therapeatics held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Maze Therapeatics by DAFNA Capital Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $1.0M 35k 29.85

More positions owned by DAFNA Capital Management

Revolution Medicines (RVMD)
Spdr S&p Biotech Etf Etf (XBI)
Stereotaxis Com New (STXS)
Day One Biopharmaceuticals I (DAWN)
AtriCure (ATRC)
Ideaya Biosciences (IDYA)
Xenon Pharmaceuticals (XENE)
Cytokinetics Com New (CYTK)
Compass Pathways Sponsored Ads (CMPS)
Nektar Therapeutics Com New (NKTR)
Ishares Nasdaq Biotech Indx Etf (IBB)
Arcus Biosciences Incorporated (RCUS)
Neurocrine Biosciences (NBIX)
Larimar Therapeutics (LRMR)
Bicara Therapeutics (BCAX)

View all positions for DAFNA Capital Management

Top funds holding Maze Therapeatics

Frazier Life Sciences Management
Trv Gp Iv
Arch Venture Corp
Deep Track Capital
Henderson Group
Paradigm Biocapital Advisors
BlackRock
AH Capital Management
Vanguard Group
VR Adviser
Vanguard Capital Management
Alphabet
Logos Global Management
General Catalyst Group Management
TRV GP V

View all funds holding Maze Therapeatics